SLCO1B1 and Hyperbilirubinemia: Additionally, it has also been demonstrated that SLCO1B1 polymorphisms, particularly the *5/*5 genotype, may be associated with an increased risk for statin-induced myopathy and hyperbilirubinemia [36].